TcLand Expression Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 11
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $6.18M
Latest Deal Amount
  • Investors
  • 1

TcLand Expression General Information

Description

Developer of biomarkers. The company is engaged in the development of immunoprofiling and gene expression biomarkers for kidney transplantation and auto-immune disorders.

Contact Information

Formerly Known As
TcLand
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Primary Office
  • 35 Rue du Fort
  • 68330 Huningue
  • France
+33 03 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TcLand Expression Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 23-Dec-2014 $6.18M Completed Generating Revenue
3. Merger/Acquisition 01-Jul-2013 000.00 Completed Generating Revenue
2. Later Stage VC 17-Jun-2011 $1.72M $13.8M Completed Generating Revenue
1. Early Stage VC (Series A) 14-Dec-2007 $12.1M $12.1M Completed Startup
To view TcLand Expression’s complete valuation and funding history, request access »

TcLand Expression Patents

TcLand Expression Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20150240304-A1 Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs Abandoned 25-Jan-2011 0000000000
EP-2668287-A2 Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) or anti-inflammatory biological drugs Granted 25-Jan-2011 0000000000
EP-2668287-B1 Genes and genes combinations based on gene mknk1 predictive of early response or non response of subjects suffering from rheumatoid arthritis to tnf-alpha blocking monoclonal antibody Active 25-Jan-2011 0000000000 0
CA-2793137-A1 Genes and genes combinations predictive of early response or non response of subjects suffering from inflammatory disease to cytokine targeting drugs (cytd) Abandoned 24-Mar-2010 0000000000
JP-2013526845-A Genes and combinations of genes that predict an initial response or non-response of a subject suffering from an inflammatory disease to a cytokine targeted drug (cytd) Withdrawn 24-Mar-2010 C12Q1/6809

TcLand Expression Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TcLand Expression Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Auriga Partners (Paris) Venture Capital Minority 000 0000 000000 0
Debiopharm Innovation Fund Corporate Venture Capital Minority 000 0000 000000 0
European Regional Development Fund Other Minority 000 0000 000000 0
OSEO Innovation Venture Capital Minority 000 0000 000000 0
Quest For Growth Asset Manager Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »